Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 603

1.

Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.

Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R.

Oncotarget. 2018 Jun 5;9(43):27074-27086. doi: 10.18632/oncotarget.25478. eCollection 2018 Jun 5.

2.

Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer.

Rosell R, Karachaliou N.

EBioMedicine. 2018 Jun 18. pii: S2352-3964(18)30209-3. doi: 10.1016/j.ebiom.2018.06.007. [Epub ahead of print] No abstract available.

3.

Migration and survival of Atlantic salmon Salmo salar smolts in a large natural lake.

Kennedy RJ, Rosell R, Millane M, Doherty D, Allen M.

J Fish Biol. 2018 Jun 8. doi: 10.1111/jfb.13676. [Epub ahead of print]

PMID:
29882213
4.

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.

Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Lee M, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Wu YL.

J Clin Oncol. 2018 Jun 4:JCO2018787994. doi: 10.1200/JCO.2018.78.7994. [Epub ahead of print]

PMID:
29864379
5.

Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.

Gregorc V, Lazzari C, Karachaliou N, Rosell R, Santarpia M.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S165-S170. doi: 10.21037/tlcr.2018.03.19. No abstract available.

6.

Liquid biopsy for lung cancer early detection.

Santarpia M, Liguori A, D'Aveni A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, Lazzari C, Altavilla G, Rosell R.

J Thorac Dis. 2018 Apr;10(Suppl 7):S882-S897. doi: 10.21037/jtd.2018.03.81. Review.

7.

Coordinated strategies for early detection of lung cancer.

Rosell R.

J Thorac Dis. 2018 Apr;10(Suppl 7):S776. doi: 10.21037/jtd.2018.04.10. No abstract available.

8.

Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.

Codony-Servat J, García-Roman S, Molina-Vila MÁ, Bertran-Alamillo J, Giménez-Capitán A, Viteri S, Cardona AF, D'Hondt E, Karachaliou N, Rosell R.

J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30592-6. doi: 10.1016/j.jtho.2018.04.030. [Epub ahead of print]

PMID:
29751136
9.

Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?

Lazzari C, Karachaliou N, Bulotta A, Viganó M, Mirabile A, Brioschi E, Santarpia M, Gianni L, Rosell R, Gregorc V.

Ther Adv Med Oncol. 2018 Apr 6;10:1758835918762094. doi: 10.1177/1758835918762094. eCollection 2018. Review.

10.

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer.

Attili I, Karachaliou N, Bonanno L, Berenguer J, Bracht J, Codony-Servat J, Codony-Servat C, Ito M, Rosell R.

Ther Adv Med Oncol. 2018 Apr 2;10:1758835918763744. doi: 10.1177/1758835918763744. eCollection 2018.

11.

Clinical assessment of immune-related adverse events.

Sosa A, Lopez Cadena E, Simon Olive C, Karachaliou N, Rosell R.

Ther Adv Med Oncol. 2018 Mar 30;10:1758835918764628. doi: 10.1177/1758835918764628. eCollection 2018. Review.

12.

Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges.

Karachaliou N, Rosell R.

Ther Adv Med Oncol. 2018 Mar 22;10:1758835918763723. doi: 10.1177/1758835918763723. eCollection 2018. No abstract available.

13.

New insights on pestivirus infections in transhumant sheep and sympatric Pyrenean chamois (Rupicapra p. pyrenaica).

Colom-Cadena A, Espunyes J, Cabezón O, Fernández-Aguilar X, Rosell R, Marco I.

Vet Microbiol. 2018 Apr;217:82-89. doi: 10.1016/j.vetmic.2018.03.003. Epub 2018 Mar 9.

PMID:
29615262
14.

The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer.

Lee CK, Lord S, Marschner I, Wu YL, Sequist L, Rosell R, Fukuoka M, Mitsudomi T, Asher R, Davies L, Gebski V, Gralla R, Mok T, Chih-Hsin Yang J.

J Thorac Oncol. 2018 Jun;13(6):792-800. doi: 10.1016/j.jtho.2018.03.010. Epub 2018 Mar 23.

PMID:
29580950
15.

RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice Variants.

Teixidó C, Giménez-Capitán A, Molina-Vila MÁ, Peg V, Karachaliou N, Rodríguez-Capote A, Castellví J, Rosell R.

Arch Pathol Lab Med. 2018 Apr;142(4):474-479. doi: 10.5858/arpa.2017-0134-RA.

PMID:
29565207
16.

Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion.

Aguado C, Gil MD, Yeste Z, Giménez-Capitán A, Teixidó C, Karachaliou N, Viteri S, Rosell R, Molina-Vila MA.

Onco Targets Ther. 2018 Mar 1;11:1117-1120. doi: 10.2147/OTT.S148363. eCollection 2018.

17.

An innovative mesothelioma treatment based on miR-16 mimic loaded EGFR targeted minicells (TargomiRs).

Viteri S, Rosell R.

Transl Lung Cancer Res. 2018 Feb;7(Suppl 1):S1-S4. doi: 10.21037/tlcr.2017.12.01. No abstract available.

18.

Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.

Rosell R, Karachaliou N.

Lancet Oncol. 2018 Mar;19(3):e126. doi: 10.1016/S1470-2045(18)30071-8. No abstract available.

PMID:
29508751
19.

Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.

Gonzalez-Cao M, Mayo de Las Casas C, Jordana Ariza N, Manzano JL, Molina-Vila MÁ, Soriano V, Puertolas T, Balada A, Soria A, Majem M, Montagut C, Muñoz E, Rodriguez-Abreu D, Perez E, Garcia A, Cortes J, Drozdowskyj A, Karachaliou N, Rosell R; Spanish Melanoma Group.

Melanoma Res. 2018 Jun;28(3):195-203. doi: 10.1097/CMR.0000000000000432.

PMID:
29481492
20.

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.

Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, Yang J, Cai X, Wang Z, Hu C, Drozdowskyj A, Servat CC, Servat JC, Ito M, Attili I, Aldeguer E, Capitan AG, Rodriguez J, Rojas L, Viteri S, Molina-Vila MA, Ou SI, Okada M, Mok TS, Bivona TG, Ono M, Cui J, Cajal SRY, Frias A, Cao P, Rosell R.

EBioMedicine. 2018 Mar;29:112-127. doi: 10.1016/j.ebiom.2018.02.001. Epub 2018 Feb 5.

21.

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.

Karachaliou N, Gonzalez-Cao M, Crespo G, Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, Teixido C, Molina-Vila MA, Viteri S, De Los Llanos Gil M, Algarra SM, Perez-Ruiz E, Marquez-Rodas I, Rodriguez-Abreu D, Blanco R, Puertolas T, Royo MA, Rosell R.

Ther Adv Med Oncol. 2018 Jan 18;10:1758834017749748. doi: 10.1177/1758834017749748. eCollection 2018.

22.

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).

Moya-Horno I, Viteri S, Karachaliou N, Rosell R.

Ther Adv Med Oncol. 2018 Jan 9;10:1758834017745012. doi: 10.1177/1758834017745012. eCollection 2018. Review.

23.

Possible application of circulating free tumor DNA in non-small cell lung cancer patients.

Karachaliou N, Sosa AE, Molina MA, Centelles Ruiz M, Rosell R.

J Thorac Dis. 2017 Oct;9(Suppl 13):S1364-S1372. doi: 10.21037/jtd.2017.09.59. Review.

24.

An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.

Mayo-de-Las-Casas C, Garzón Ibáñez M, Jordana-Ariza N, García-Peláez B, Balada-Bel A, Villatoro S, Malapelle U, Karachaliou N, Troncone G, Rosell R, Molina-Vila MA.

Expert Rev Mol Diagn. 2018 Jan;18(1):35-45. doi: 10.1080/14737159.2018.1407243. Epub 2017 Nov 26.

PMID:
29172773
25.

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.

Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martínez-Cardús A, Marín-Aguilera M, Horndler C, Martínez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martín-Richard M, Alonso V, Escudero P, Fernández-Martos C, Feliu J, Méndez JC, Méndez M, Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, García-Albéniz X, Camps J, Maurel J.

Br J Cancer. 2017 Dec 5;117(12):1777-1786. doi: 10.1038/bjc.2017.279. Epub 2017 Nov 9.

PMID:
29123263
26.

Cross-cultural adaptation and validation of the Spanish version of the Paediatric Throat Disorders Outcome Test (T-14).

Larrosa F, Samara L, Esteller E, Dura MJ, Escamilla Y, Alberti A, Rosell R, Hopkins C.

Clin Otolaryngol. 2018 Apr;43(2):598-603. doi: 10.1111/coa.13029. Epub 2017 Nov 27.

PMID:
29119714
27.

The combination of checkpoint immunotherapy and targeted therapy in cancer.

Karachaliou N, Gonzalez-Cao M, Sosa A, Berenguer J, Bracht JWP, Ito M, Rosell R.

Ann Transl Med. 2017 Oct;5(19):388. doi: 10.21037/atm.2017.06.47. Review.

28.

Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.

Wills B, Cardona AF, Rojas L, Ruiz-Patiño A, Arrieta O, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Cuello M, Pino LE, Rolfo C, Rosell R, Zatarain-Barrón ZL; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).

Anticancer Res. 2017 Nov;37(11):6429-6436.

PMID:
29061829
29.

Homage to the titans of Chinese investigation and the race for lung cancer curability.

Rosell R.

J Thorac Dis. 2017 Oct;9(Suppl 11):S1150. doi: 10.21037/jtd.2017.09.145. No abstract available.

30.

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS.

Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.

PMID:
28958502
31.

First report of the novel atypical porcine pestivirus in Spain and a retrospective study.

Muñoz-González S, Canturri A, Pérez-Simó M, Bohórquez JA, Rosell R, Cabezón O, Segalés J, Domingo M, Ganges L.

Transbound Emerg Dis. 2017 Dec;64(6):1645-1649. doi: 10.1111/tbed.12699. Epub 2017 Sep 21.

PMID:
28941140
32.

BRAFV600E and BRAF-inactivating mutations in NSCLC.

Rosell R, Karachaliou N.

Lancet Oncol. 2017 Oct;18(10):1286-1287. doi: 10.1016/S1470-2045(17)30678-2. Epub 2017 Sep 11. No abstract available.

PMID:
28919012
33.

Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions.

Mayo-de-Las-Casas C, Jordana-Ariza N, Garzón-Ibañez M, Balada-Bel A, Bertrán-Alamillo J, Viteri-Ramírez S, Reguart N, Muñoz-Quintana MA, Lianes-Barragan P, Camps C, Jantús E, Remon-Massip J, Calabuig S, Aguiar D, Gil ML, Viñolas N, Santos-Rodríguez AK, Majem M, García-Peláez B, Villatoro S, Pérez-Rosado A, Monasterio JC, Ovalle E, Catalán MJ, Campos R, Morales-Espinosa D, Martínez-Bueno A, González-Cao M, González X, Moya-Horno I, Sosa AE, Karachaliou N, Rosell R, Molina-Vila MA.

Ann Oncol. 2017 Sep 1;28(9):2248-2255. doi: 10.1093/annonc/mdx288.

PMID:
28911086
34.

IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.

Etxaniz O, Carrato C, de Aguirre I, Queralt C, Muñoz A, Ramirez JL, Rosell R, Villà S, Diaz R, Estival A, Teixidor P, Indacochea A, Ahjal S, Vilà L, Balañá C.

J Neurooncol. 2017 Nov;135(2):273-284. doi: 10.1007/s11060-017-2570-1. Epub 2017 Sep 7.

PMID:
28884377
35.

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.

Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-Capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ, Rosell R.

Nat Commun. 2017 Sep 4;8(1):410. doi: 10.1038/s41467-017-00450-6.

36.

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.

Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G, Rosell R.

Lung Cancer (Auckl). 2017 Aug 18;8:109-125. doi: 10.2147/LCTT.S119644. eCollection 2017. Review.

37.

Tracking MET de-addiction in lung cancer: A road towards the oncogenic target.

Pilotto S, Carbognin L, Karachaliou N, Ma PC, Rosell R, Tortora G, Bria E.

Cancer Treat Rev. 2017 Nov;60:1-11. doi: 10.1016/j.ctrv.2017.08.002. Epub 2017 Aug 20. Review.

PMID:
28843992
38.

Monitoring of Schmallenberg virus in Spanish wild artiodactyls, 2006-2015.

García-Bocanegra I, Cano-Terriza D, Vidal G, Rosell R, Paniagua J, Jiménez-Ruiz S, Expósito C, Rivero-Juarez A, Arenas A, Pujols J.

PLoS One. 2017 Aug 16;12(8):e0182212. doi: 10.1371/journal.pone.0182212. eCollection 2017.

39.

Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets.

Best MG, Sol N, In 't Veld SGJG, Vancura A, Muller M, Niemeijer AN, Fejes AV, Tjon Kon Fat LA, Huis In 't Veld AE, Leurs C, Le Large TY, Meijer LL, Kooi IE, Rustenburg F, Schellen P, Verschueren H, Post E, Wedekind LE, Bracht J, Esenkbrink M, Wils L, Favaro F, Schoonhoven JD, Tannous J, Meijers-Heijboer H, Kazemier G, Giovannetti E, Reijneveld JC, Idema S, Killestein J, Heger M, de Jager SC, Urbanus RT, Hoefer IE, Pasterkamp G, Mannhalter C, Gomez-Arroyo J, Bogaard HJ, Noske DP, Vandertop WP, van den Broek D, Ylstra B, Nilsson RJA, Wesseling P, Karachaliou N, Rosell R, Lee-Lewandrowski E, Lewandrowski KB, Tannous BA, de Langen AJ, Smit EF, van den Heuvel MM, Wurdinger T.

Cancer Cell. 2017 Aug 14;32(2):238-252.e9. doi: 10.1016/j.ccell.2017.07.004.

40.

Corrigendum to "Characterization of the efficiency and uncertainty of skimmed milk flocculation for the simultaneous concentration and quantification of water-borne viruses, bacteria and protozoa" [J. Microbiol. Methods 134 (2017) 46-53].

Gonzales-Gustavson E, Cárdenas-Youngs Y, Calvo M, da Silva MFM, Hundesa A, Amorós I, Moreno Y, Moreno-Mesonero L, Rosell R, Ganges L, Araujo R, Girones R.

J Microbiol Methods. 2017 Nov;142:96. doi: 10.1016/j.mimet.2017.07.016. Epub 2017 Aug 9. No abstract available.

41.

African swine fever virus infection in Classical swine fever subclinically infected wild boars.

Cabezón O, Muñoz-González S, Colom-Cadena A, Pérez-Simó M, Rosell R, Lavín S, Marco I, Fraile L, de la Riva PM, Rodríguez F, Domínguez J, Ganges L.

BMC Vet Res. 2017 Aug 1;13(1):227. doi: 10.1186/s12917-017-1150-0.

42.

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.

Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G.

Drug Des Devel Ther. 2017 Jul 5;11:2047-2063. doi: 10.2147/DDDT.S113500. eCollection 2017. Review.

43.

Brain metastases in patients with EGFR-mutant non-small-cell lung cancer.

Rosell R, Karachaliou N.

Lancet Respir Med. 2017 Sep;5(9):669-671. doi: 10.1016/S2213-2600(17)30265-5. Epub 2017 Jul 19. No abstract available.

PMID:
28734820
44.

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients.

Bottai G, Raschioni C, Székely B, Di Tommaso L, Szász AM, Losurdo A, Győrffy B, Ács B, Torrisi R, Karachaliou N, Tőkés T, Caruso M, Kulka J, Roncalli M, Santoro A, Mantovani A, Rosell R, Reis-Filho JS, Santarpia L.

NPJ Breast Cancer. 2016 Nov 2;2:16033. doi: 10.1038/npjbcancer.2016.33. eCollection 2016.

45.

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R.

Lung Cancer. 2017 Jun;108:154-160. doi: 10.1016/j.lungcan.2017.03.009. Epub 2017 Mar 22.

PMID:
28625629
46.

YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma.

Guo T, Zhao S, Wang P, Xue X, Zhang Y, Yang M, Li N, Li Z, Xu L, Jiang L, Zhao L, Ma PC, Rosell R, Li J, Gu C.

Oncotarget. 2017 Jul 18;8(29):48110-48125. doi: 10.18632/oncotarget.18262.

47.

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).

Cardona AF, Arrieta O, Zapata MI, Rojas L, Wills B, Reguart N, Karachaliou N, Carranza H, Vargas C, Otero J, Archila P, Martín C, Corrales L, Cuello M, Ortiz C, Pino LE, Rosell R, Zatarain-Barrón ZL; CLICaP.

Target Oncol. 2017 Aug;12(4):513-523. doi: 10.1007/s11523-017-0497-2.

PMID:
28620690
48.

Neutrophils dominate the immune landscape of non-small cell lung cancer.

Teixidó C, Rosell R.

J Thorac Dis. 2017 May;9(5):E468-E469. doi: 10.21037/jtd.2017.04.55. No abstract available.

49.

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators.

N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.

50.

A bivalent dendrimeric peptide bearing a T-cell epitope from foot-and-mouth disease virus protein 3A improves humoral response against classical swine fever virus.

Bohórquez JA, Defaus S, Muñoz-González S, Perez-Simó M, Rosell R, Fraile L, Sobrino F, Andreu D, Ganges L.

Virus Res. 2017 Jun 15;238:8-12. doi: 10.1016/j.virusres.2017.05.020. Epub 2017 May 30.

PMID:
28571760

Supplemental Content

Loading ...
Support Center